A multi-center, open-label Phase I trial will evaluate the safety and tolerability of SRF231 in multiple ascending doses in patients with advanced solid tumors and hematologic malignancies

Trial Profile

A multi-center, open-label Phase I trial will evaluate the safety and tolerability of SRF231 in multiple ascending doses in patients with advanced solid tumors and hematologic malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs SRF 231 (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Mar 2018 New trial record
    • 20 Mar 2018 According to a Surface Oncology media release, the first patient was treated in this phase I trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top